Prosensa Holding N.V. (RNA) Reports Q3 Loss of EUR 0.29/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Prosensa Announces 3rd Quarter 2014 Financial Results and Recent Corporate Developments
November 17, 2014 7:00 AM ESTRolling NDA submission drisapersen underway EMA filing for conditional approval anticipated to follow NDA submission Re-dosing has commenced in United States, Belgium & Sweden Cash & cash equivalents at quarter-end 62M
LEIDEN, The Netherlands, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported financial results for the third quarter ending September 30, 2014 and provided an update on the regulatory plans and re-dosing for drisapersen, our lead exon-skipping drug candidate, and... More
